Immucell (ICCC) Return on Equity ROE from the second quarter 2026 to second quarter 2025 and annually, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Immucell Corporation  (NASDAQ: ICCC)

Immucell's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Immucell in the second quarter 2026?
Immucell Corporation achieved a return on average equity (ROE) of 2.68 % in its second quarter 2026, this is above ICCC's average return on equity of -3.05%.
Immucell Corporation shareholder's equity over the 12 months ending in its second quarter 2026 are valued at $29 million

While the company's net income was fading, Immucell was able to improve its ROE compared to the first quarter 2026.

Within the In Vitro & In Vivo Diagnostic Substances industry only one company had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2026 from 2037 to 2421.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Equity Change 5.05 % 0.49 % -1.68 % 12.83 % -
Y / Y Net Income Change 265.56 % 34.18 % - - -
Net Income (TTM) in Millions 1 -1 -1 2 2
Return On Equity (TTM) 2.68 % -1.88 % -3.6 % 8 % 6.25 %
ICCC's Total Ranking # 2421 # 2037 # 2166 # 1420 # 1495
Equity (TTM) in Millions 31 29 27 30 30
Seq. Equity Change 7.69 % 7.69 % -9.21 % -0.22 % 3.01 %
Seq. Net Income Change -5.51 % - - - -65.32 %

Back to ICCC Management Effectiveness >> ICCC's 5 Years Annual ROE >> Compare ICCC ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 2
Sector # 176
Overall # 2421

Return On Equity Statistics
High Average Low
11.97 %
-3.05 %
-22.63 %
(Dec 31 2015)   (Sep 30 2023)





ICCC Annual Return On Equity (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Equity in Millions 27 28 25 30 33
Y / Y Equity Change -1.68 % 10.1 % -17.73 % -6.74 % 15.25 %
Net Income in Millions -1 -2 -6 -2 0
Y / Y Net Income Change - - - - -
Return On Equity -3.84 % -7.84 % -23.1 % -8.21 % -0.24 %

Back to ICCC Management Effectiveness >> ICCC's 5 Years Annual ROE >> Compare ICCC ROE to its Competitors




More Return On Equity Ratios
In Vitro & In Vivo Diagnostic Substances Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
ICCC's' Return on Equity at Yahoo Finance
ICCC's Roe Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for ICCC's Competitors
Subscribers only: Roe for Immucell's Suppliers
Subscribers only: Return On Equity for ICCC's Customers




Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector ROE
Vericel Corporation  6.91 %
The Cooper Companies Inc   6.90 %
Siga Technologies Inc  6.74 %
Merck and Co Inc   6.59 %
Zimmer Biomet Holdings Inc   6.36 %
National Vision Holdings Inc   5.71 %
Conmed Corporation  5.51 %
Pfizer Inc  4.91 %
Privia Health Group Inc   4.23 %
Becton Dickinson And Company  3.79 %
Alkermes Plc   3.72 %
Lifemd Inc   3.47 %
Lifestance Health Group Inc   3.39 %
Revvity Inc  3.27 %
Bio rad Laboratories Inc   3.15 %
Envista Holdings Corporation  3.08 %
Immucell Corporation  2.68 %
Surgery Partners Inc   2.63 %
Mimedx Group Inc   2.61 %
Cormedix Inc   2.18 %
Atricure Inc   2.14 %
Pacira Biosciences inc   2.13 %
Warby Parker Inc   2.06 %
Repligen Corp  1.98 %
Arvinas Inc   1.91 %
Waters Corporation  1.88 %
Omada Health Inc   1.84 %
Radnet Inc   1.42 %
Icu Medical Inc  1.41 %
Biomarin Pharmaceutical Inc  1.18 %

Date modified: 2026-09-26T06:50:52+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.